Cosmos Health Inc.
No SEC Form 4 filings for $COSM in the last 30 days.
See all $COSM insider activity →Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cosm_ex991.htm PRESS RELEASE cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurcha
Cosmos Health (COSM) signed an exclusive 5-year distribution deal with Innova Healthcare in Saudi Arabia for its Sky Premium Life nutraceutical brand. The initial order is 126,000 units, with over 5 million expected. COSM stock is up 10.94% to $0.21.
Cosmos Health Inc. (COSM) signed an exclusive 5-year distribution agreement with Innova Healthcare for its Sky Premium Life supplements in Saudi Arabia. The deal includes an initial 126,000-unit order and expects over 5 million units in 5 years. Innova operates 250+ pharmacies and is backed by major investors. The Saudi nutraceuticals market is valued at $3.26B, growing to $5.96B by 2033.
Over the past 7 days, alphai's AI scored 5 news stories mentioning COSM (Cosmos Health Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.
Recent COSM coverage spans corporate actions, earnings and financial news.
Revenue up ~29% YoY and a new buyback suggest improving fundamentals, potentially supporting the stock price.
The Saudi deal expands market reach and could boost revenue, supporting short-term upside.
The Saudi distribution deal expands Cosmos Health's market reach and could boost revenue from the growing nutraceutical market.
Earnings miss on loss may pressure price; buyback could provide support.
Strong top-line growth and share buyback may support short-term price upside.
alphai scores every news story that mentions COSM with an AI model for sentiment and relevance, and aggregates insider trades from Cosmos Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cosm_ex991.htm PRESS RELEASE cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurcha
2 min readCosmos Health (COSM) signed an exclusive 5-year distribution deal with Innova Healthcare in Saudi Arabia for its Sky Premium Life nutraceutical brand. The initial order is 126,000 units, with over 5 million expected. COSM stock is up 10.94% to $0.21.
2 min readCosmos Health Inc. (COSM) signed an exclusive 5-year distribution agreement with Innova Healthcare for its Sky Premium Life supplements in Saudi Arabia. The deal includes an initial 126,000-unit order and expects over 5 million units in 5 years. Innova operates 250+ pharmacies and is backed by major investors. The Saudi nutraceuticals market is valued at $3.26B, growing to $5.96B by 2033.
2 min readCosmos Health Inc. (COSM) reported a wider net loss of $6.09M in Q2 2026, up from $2.83M in Q2 2025, due to higher fair value expenses and interest costs, despite a 28.8% revenue increase to $18.99M. Adjusted EBITDA loss narrowed. The company expanded product lines and secured potential financing. Cash position was $2.44M. Shares fell 6.58% to $0.19.
2 min readCosmos Health reported Q2 2026 revenue of $19.0M, up 29% YoY, with adjusted gross profit increasing 58%. Total liabilities decreased 13%, and stockholders' equity rose 12%. The company's share repurchase program is active, with 5.1M shares repurchased so far. Revenue growth was driven by all core segments, including Decahedron, Cana Laboratories, and CosmoFarm.
2 min readCosmos Health (NASDAQ:COSM) said it expanded its Sky Premium Life distribution partnership with Pharma Cell in Albania. Average monthly orders already exceed 4,500 units, and annualized orders are projected to top 54,000. The products are distributed nationwide via Pharma Cell’s network and recommended by doctors and healthcare professionals.
2 min readCosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 274,000 shares in the open market at an average price of about $0.2554 per share. Total buybacks under its up to $5 million program reached 5,112,000 shares for about $1.11 million. The program expires Dec. 31, 2026.
3 min readCosmos Health Inc. (COSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. cosm_8k.htm 0001474167 false --12-31 0001474167 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act o
3 min readCosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 250,000 shares in the open market at an average price of about $0.2782 per share. Total repurchases under its up to $5 million program reached 4,838,000 shares for about $1.04 million. The program expires Dec. 31, 2026 and may continue subject to conditions.
2 min readCosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 100,000 shares in the open market at an average price of about $0.2928. Total repurchases under its up to $5 million program reached 4,588,000 shares for about $970,000. The company plans to continue repurchases through Dec. 31, 2026.
2 min read
